<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 363 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page362.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=363">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 363 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 363</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=363"><img src="../thumb/363.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>326 / 2020-04                                                             Immunological - 24.1
   nephrit., proteinur., erect.dysfunct., periph.oed., incision.hern.pain,   Paeds:  with concom. immunosuppres.with improvem.noted with discont.,
   impair.heal., lymphoma/ lymphoproliferat.dis./skin malign. depend.  Polyarticul.juven.idiopath.arthrit.2 yrs. (&lt;10kg) & old (US   psorias.recurr.report.when challeng.with diff. TNF block., consid.
   on immunosuppress.regim.     regimen): 10 - 15 kg: 10 mg every other wk. 15 - &lt;30 kg: 20 mg   discont.in sev.psorias. cases & those not show.improvem./worsen.
   Special precautions: Combin.with agents other than ciclospor.for   every other wk. ≥30 kg: 40 mg every other wk. Clinic.respons. usu-  despite topic.treatm.,
   microemuls./basiliximab & corticoster.not adeq.investig., combin.with   al within 12 wks.of treatm. Reconsid.treatm.if no respons.with this
   thymoglobulin induct.assoc.with great.infect.cause mortality, incr.risk   time. Methotrex./glucocortic./ NSAID’s and/or analgesics maybe   IMURAN, (Aspen Pharmacare: Pharma) Pharmacare [P/S]
   of lymphoma/malign.esp.of skin when regim.of immunosuppress.  cont.dur. treatm.  Azathioprine.
   admin., monit.for skin neoplasms & advis.limit.UV expos., over-im-  Paed.Crohn’s Dis: &lt;40kg: Init.dos (day 1): 80 mg (as 2x40 mg inj.  Indications: Immuno-suppres.agent, organ transplants, auto-
   munosuppress. predipos. to infects.esp.with opportunist. pathogens,   in one day), follow.by 40 mg two wks.later (day 15). Begin maint.  immune dis.
   cytomegalovir.prophylax.recomm.x3 mnths. aft.transplantat.partic.for   dos.2 wks. later (day 29) as 20 mg every other wk.  (S4) TABS, [P/S] D/26/98.
   those at risk, monit. bld.conc.in hepat impairm./dur. concom. admin.  &gt;40kg: Init.dos (day 1): 160 mg (as 4x40 mg inj.in one day or   732516-005: 50 mg, 100, R2 069,10
   of strong CYP3A4 induc.& inhibit./when switch. formulat./if ciclo-  2x40 mg/day for 2 consecut.days), follow.by 80 mg two wks.later   (S4) INJ, [P/S] H2746.
   spor.dos.mark.reduc., reduc.dos.to approx.one half of norm.dos.with   (day 15). Begin maint.dos.2 wks. later (day 29) as 40 mg every other   732524-008: 50 mg/vial, R922,50
   mod./sev.hepat.impairm.(Child-Pugh B/ C)., eval. risk vs. benefit.bef.  wk. Some pts.may benef.from incr.freq.to wkly.if dis.flare/inadeq.   For further details refer to manufact.prod.lit.
   co-admin.strong 3A4-inhibit./ induc.as not recomm., monit for rhab-  respon.dur.maint.  MICOMUNE 500, (Accord) Ingwe [P/S]
   domyolys.& other adverse events assoc.with HMG-CoA reduct. in-  Paed.plaque psorias: 0,8 mg/kg (up to max. 40 mg/dos.) SC   Mycophenolate mofetil
   hibit., live vaccinat.less effect., adeq.contracept. dur. treatm.& x8 wks.  wkly x1st two dos then every other wk.thereaft. Carefully consid.  Indications: Organ reject.prophylax.in allogeneic ren./hepat.or card.
   aft.stop., ac.reject.episod. high. in black pts., effic.& safety data for   ther.beyond 16 wks. in pts.not respond. If retreatm.indicat.follow   transpl.concom.with cyclosporin & corticoster.
   use in black pts.too limit.to allow recommendat., no adeq. data for   above dos.& treatm.guid.  (S4) TABS, 48/32.2/1156
   use in childr.& adolesc., limit.exper. in pts.&gt;than 65 yrs., monit.bld.  Adolesc.hidradenit.suppurativa from 12 yrs. weigh.at least   722961-001: 500 mg, 50, R1 172,68
   trough lev.to therapeut. range of 3-8 ng/ml, improv.ren.funct.& low.  30 kg: No clinic.trails. Posology determ.from pharmacokinet.   Dosage: Do not crush/chew tabs.Init.dos.to be giv.as soon as poss.
   incid.of adverse events assoc.with reduc. ciclospor. expos., avoid long   model. & simulat.   aft. ren./ card./hepat.transpl.
   term use with full dos. concom ciclospor.in ren.transplantat., reduc.   Recomm.dos: 80 mg SC at wk.0 follow.by 40 mg every other wk.start.  Ren.reject.prophylax: Adults: Init.dos.to be admin. with. 72 hrs.
   ciclospor. dos. in maint.phase of card.transplants as tol.to improve   at wk.1  of transpl. Recomm.dos: 1 g 2xdly. Childr.3 mnths.-18 yrs: May be
   kidn.funct., bef.init.or contin. immunosuppress. regimen consid.risk/  Contin.antibiot.if necess. Use top.antisept.wash on les on dly.basis   prescr.to childr.with body surf.area great.than 1,5 m 2  at 1 g 2xdly dos.
   benef.in hyperlipidem.pts.or sev.refract.hyperlipidaem., reg. monit of   dur.treatm. Recons.continther.if no benef.aft.12 wks. Treatm.may be   Card.reject.prophylax: Adults: 1,5 g 2xdly start. within 5 days
   ren.funct., meds.known to have deleteroius eff.on ren.funct., safety   re-introduc.if treat.interrupt. Eval.benef.of long term.treatm.periodic.  of card.transpl.
   in porphyr.not establish.    Chron.non-infect.uveit.from 2 yrs: May be used in combinat.  Hepat.reject.prophylax: Adults: 1,5 g 2xdly. Init. ASAP aft.transpl.
   Drug interactions: Bld conc.incr.by P-glycoprot. inhibit., conc.  with methotrex/other non-biolog. immunomodulat. agents bas.  First/refract.ren.reject.treatm: Adults: 1,5 g 2xdly.
   of drugs elimin.by CYP3A4 & CYP2D6 enzym.incr., bioavail.incr.by   on clinic.judgm.  Contraindications: Pregn.& lactat.
   ciclosporin, rifampicin incr. clear., CYP3A4 & PgP inhibit.incr.bld.lev.  &lt;30 kg: 20 mg every other wk. &gt;30 kg: 40 mg every other wk. Load.dos:   Side effects: Infect., sepsis, abscess, flu, meningit., infect.endo-
   (eg. antifungs. /macrolide antibiot./Ca chann.block./ cisapride/ me-  &lt;30 kg: 40 mg. &gt;30 kg: 80 mg. May be admin.1 wk.prior to start.maint. ther.  cardit., neoplasms, cysts, bld. dyscras., ecchymos., polycythaem.,
   toclopramide/bromocript./cimetid. /danazol & HIV prot.inhibit.), CY-  Contraindications: Mod.to sev.CF (NYHA class III/IV), act.TB/  bone marr. depress., pure red cell aplas., diab.mellit., Cushing syndr.,
   P3A4 induc. decr. bld.lev.(eg.St John’s Wort/anticonvuls./ efavirenz/   other sev.infects.,   hypothyroid., hypercholesterolaem., hyperglycaem., hyperkalaem.,
   nevirapine & rifabutin).     Side effects: V.common: U&LRTI, leucopen.incl. neutropen.&   hypokalaem., hypomagnesaem., hyponatraem., hyperuricaem.,
   ELIDEL, MEDA Pharma South Africa (Pty) Ltd  agranulocytos., anaem., incr.lipids, headache, abdom.pain, N&V,   hypervolaem., hypoproteinaem., hypophosphataem., metabol.
                                elev.liv.enzymes, skin rash incl.exfoliat.rash, musculoskelet.pain,
   See Section 14.9             inj. site react. Common: Syst.infects.incl.sepsis/ candiadias.&   acidos., alkalos., dehydrat., incr.alkal.phosphat., hyperlipidaem.,
                                                              hypocalcaem., hypoglycaem., gout, psych./eye /card./ GI /ren.&
   HUMIRA, Abbvie [P/S] &       influenza, intest.infects., skin & soft tiss. infects.incl.H.zoster, ear   urin./parathyroid disords., anx., CNS effs., headache, dizzin., tremor,
   Adalimumab                   infects., oral infects. incl.H.simplex/oral herpes & tooth infects.,   convuls., neuropathy, hyperton., deafn., conjuctivit., eye haemorrh.,
   Indications: Adults: Mod.to sev.adult rheumat. arthrit. incl.recent.  reproduct. tract infects., UTI incl.pyelonephrit., fung. infects., joint   cataract, ear/chest/back/pelv. pain, tinnit., ang. pect., dysrhythm.,
   diagnos.pts.not prev.treat.with methotrex. Used in combinat.with   infects., benign neoplasm, skin Ca excl.melanoma, thrombocytopen.,   card.arrest, CHF, hyper-/ hypotens., oed., pulm.hypertens., vasosp.,
   methotrex./ monother. when intol.to methotrex./if contin. treatm.   leucocytos., hypersens., hypokalaem./-calcaem., incr.uric acid, ab-  thrombos., pneumon., incr.cough., apn., sinusit., asthma, rhinit.,
   with methotrex.inappropr., psoriat.arthrit. alone/ in combinat.with   norm. bld.sod., hyperglycaem., hypophosphotaem., dehydrat., mood   pharyngit., bronchit., resp.acidos./ fail., dyspn., haemoptys., pneu-
   dis.modify.anti-rheumat. drugs., mod.to sev.chron.plaque psorias.in   alterat., anx., insomn., paraesthes.incl.hypoasthes., migraine, nerve   mothor., epistax., atelectas., incr.sputum, hypervent., resp./oral /GI
   candidat. for system.ther./photother.& other system. ther.med.less   root compress., vis.impairm., conjunctivit., blepharit., eye swell.,   monilias., TB, atyp.mycobact.infect., interstit.lung disord., pulm.fi-
   appropr., mod.to sev.nail psorias. in candidat.for system.ther., sev.  vertigo, tachycard., hypertens., flush., haematoma, cough, asthma,   bros., gingivit., gum hyperplas., pancreatit., dysphag., intest.villous
   adult axial spondyloarthrit. incl.ankylos.spondylit.when resp. to con-  dyspn., GI haemorrh., dyspeps., GORD, sicca syndr., prurit., urticar.,   atrophy, hepatit., ascit., skin reacts.incl. Herpes simpl./ zoster, alo-
   vent.ther.inadeq./NSAID intol., act. adult ankylos. spondylit.where   bruis.incl.purpura, dermatit. incl.eczema, onychoclas., hyperhydros.,   pec., hirsutism, skin Ca, sweat., chills, leg cramps, myalg., myasth.,
   respons.to convent. ther.inadeq., mod. to sev.adult Crohn’s dis.where   musc. spasm, haematur., ren.impairm., chest pain, oed., coagulat.&   arthralg., osteoporos., hyperton., UTI, hydrocele, scrot.oed., impot.,
   respons.to convent. ther.inadeq./where infliximab respons.lost/intol.  bleed.disords.incl.activ.part. thromboplast. time prolong., posit.au-  asthen., pyrex., malaise, pallor, imp.heal., hiccough, dysphon., weight
   exper., mod.to sev.act.adult ulcerat. colit when resp.to convent.ther.  toantibody tests, imp.heal. Uncommon: Opportunist.infects. & TB   gain, incr.GI adverse events.
   incl. corticoster. &/ 6-MP/ AZA inadeq./intol.to or med. contraindic.  incl.coccidioidomycos./histoplasmos & mycobact. avium complex),   Warnings and special precautions: Incr. infect. susceptibil./
   for such ther., act.mod.to sev. hidradenit. suppurativa (acne inversa)   neurolog./eye & bact. infects., lymphoma, solid organ neoplasms   poss.lymphoma & other malign. developm. esp.skin, spec.physic.in
   incl. inflamm. les.& prev.of/worsen.abscess.& drain. fistulas, non-  incl. breast Ca/lung & thyroid neoplasm, melanoma, idiopath.  attend.& at appropr. equip.facilit., limit.sun/UV light expos., incr. sus-
   infect.intermed.-/poster-& panuveit.  thrombocytopen.purpura, trem., neuropathy, diplop., deafn., tinnit.,   cept. to infect.incl.opportunist./fatal infect. & sepsis, reg.compl. bld.
   Paeds: Mod.to sev.polyarticul.juven.idiopath. arthrit. in pts.2 yrs.&   arrhythm., CHF, vasc.arter.occlus., thrombophlebit., aort.aneurysm,   counts wkly.dur.1  month, twice mthly dur..2  & 3  mnth then once/
                                                                                  rd
                                                                                nd
                                                                     st
   old.alone/in combinat.with methotrex., mod.to sev.act.paed.(6 yrs.or   COPD, interstit.lund dis., pneumonit., pancreatit., dysphag., face oed.,   mnth.dur.1  yr., discont.ther.if sev.neutropen. devel., report evid.of
                                                                   st
   old.) Crohn’s dis.where respons.to convent.ther. inadeq., sev.chron.  cholelithias., bilirub.incr.,  hepat.steatos., night sweats, scar, rhab-  any infect./unexpect.bruis./ bleed., incr.activat.of latent vir.infects.
   plaque psorias.from 4 yrs.with inadeq. respons.to/inappropr.candidat.  domyolys., SLE, noctur., ED, inflammat. Rare: Pancytopen., multiple   risk, live vacc. not to be giv.to pts. with imp.immune repons., IUD,
   for topic.-& photother., act.mod.to sev.hidradenit.suppurativa (acne   scleros., card.arrest. Post market: Anaphylax., sarcoidos., hepat.B   cons.benef.vs.risk dur. act.digest. syst. dis.incl. haemorrh./ulc./per-
   inversa) from 12 yrs.with inadeq.respons.to convent. ther., chron.  reactivtat., liv.fail., hepatit., cutan.vasculit., Stev.John.syndr., angi-  forat., avoid in rare heredit. defic.of hypoxanthine-guanine phospho-
   non-infect.uveit.from 2 yrs.  oed., new onset/psorias.worsen., erythema multiforme, alopec.,   ribosyl-transferase, concom.azathioprine not recomm., monit.MPA
   (S4) SOL.FOR INJ, 37/30.2/0252. 40 mg/0,8 ml  intestin.perforat., demyelinat. disords., CVA, lupus-like syndr., MI,   with concom.rifampicin, admin. at least 2 hrs. bef.sevelamer/other
   705335-001: sngl.pre-fill.syr., 2, R8 440,16  hepatosplen.T-cell lymphoma, leukaem., Merkel cell Ca, diverticulit.,   Ca-free phosph.bind., no data avail.for paed.card./ hepat. transpl./
   Dosage: Methotrex.& other DMARD’s may be cont. dur.treatm.   pulm.embol./-effus., pyrex.  first or refract.ren.reject.treatm., interrupt. ther./ dos.reduc.if absol.
   Admin.SC.                    Warnings and special precautions: Monit.for infects. incl.TB   neutroph.count is &lt;1,3x10 /µL, avoid direct skin/ mucous membr.
                                                                         3
   Rheumat.arthrit: Adults: 40 mg every other wk. as sngl.dos. If decr.  bef./ dur.& aft.treatm., monit.caref. if new infect.develops & discont.  cont./ expos.by inhalat., elderly, sev.chron.ren. impairm., meds.
   respons.exper.in monother.incr. to 40 mg every wk. Clinic.respons.  until clear.if sev., recurr. infect.hist./concom.immunosuppress.ther./   interfer.with enterohepat.re-circulat., alert dr.to poss.pregn., neg.
   usually within 12 wks.       underly. condits.predispos. to infect., do not init. treatm. in pres.of   pregn.test reqd. with.1 wk of init.ther.in women of childbear. po-
   Psoriat.arthrit: Adults: 40 mg every other wk.as sngl.dos.  act.infects.(chron./localis.) until control., consid.risk vs.benef.in pts.  tent., effect.contracept.advis.at least 4 wks.bef. init. ther.unt.6 wks.
   Axial spondyloarthrit.incl. ankylos.spondylit: Adults: 40 mg   expos.to TB/ travel. to high risk TB areas/endem.mycoses, prophy-  aft.discont., pregn./women of childbear. potent.not to handle tabs.,
   every other wk.as sngl.dos.  lact. anti-TB ther.with latent TB reduc. reactivat. risk, bal.benef.in   teratogen., monit. with concom. tacrolimus,., no data avail.for card./
   Chrohn’s dis: Adults: 160 mg at wk.0 admin.as 4 inj.in one day or as   HIV posit.pts.& monit. HIV posit.pts.caref., discont.TNF-block.ther.if   hepat.transpl.pts.with sev.chron.ren. impairm., no data avail.for card.
   2 inj./day x2 consec.days, then 80 mg at wk.2 follow.2 wks.later by   sev. fung. infect.develops until infect.control., eval.HBV risk pts.bef.  transpl.pts.with sev. hepat. parenchym.dis., limit.data for hepat.
   40 mg every other wk. Poss.addit.benefit with incr.dos.freq.to 40 mg   init.ther., identif.& monit.HBV carriers, concom. anti-vir.ther., prior to   transpl.pts.with concom.tacrolimus.
   wkly. Some pts.not respond.by wk.4 may benef.from cont.maint.ther   init.ther.do neurolog. exam.in non-infect.intermed.uveitis for pre-ex-  Interactions: Incr.plasma conc.of both meds. when admin.con-
   through wk.12. Reconsid. treatm.in pts.not respond.within this time   ist. centr. demyelinat.disords., pre-exist./rec. onset CNS demyelinat.  com.with acyclovir./valaciclovir/ ganciclovir/ valganciclovir, potent.
   per. Taper corticoster.accord.to clinic. guidelines dur.maint.treatm.  disords., poss.lymphoma & other malign.risk, incr.background lym-  bone marrow suppress. with concom.azathiopine, decr.plasma
   Ulcerat.colit: Adults: 160 mg at wk.0 admin.as 4 inj. in one day   phoma risk in rheumt.arthrit with long-stand.high.act.inflamm. dis.,   conc. with cholestyramine, antacids with Mg & Al. hydrox. poss.
   or as 2 inj./day x2 consec.days, then 80 mg at wk.2 follow.by 40 mg   concom.azathioprine/6 mercaptopurine incr. risk of hepatosplen.T-  decr.absorpt., reduc.MPA expos.with ciclosporin in ren.transpl.pts.,
   every other wk. Some pts.exper.decr.respons.may benef.from incr.   cell lymphoma, malign.hist./ pts. develop.malign.while on ther., rheu-  incr.tacrolimus AUC in hepat.transpl.pts., poss.incr.plasma conc.of
   dos. freq.to 40 mg wkly. Clin.respons.usual.within 2-8 wks. Cont.  mat. arthrit. pts.poss.at high.risk for leukaem. developm., exam.all   metabol. with probenecid, antibod.respons.to other vacc.dimin.with
              st
   therap.only in pts.resp.dur.1  8 wks of ther.  pts.in partic.those with extens. immunosuppress.ther.hist./psorias.  concom.live vacc., decr. expos. with rifampicin in pts.not also tak.
   Psoriasis: Adults: Init.80 mg follow.by 40 mg every other wk.start.1   pts. with PUVA treatm. hist.bef.& dur.treatm.for non-melanoma skin   ciclospor., decr.in MPA C max & AUC with sevelamer, reduc.eff.poss.
   wk.aft.init.dos. Beyond 16 wiks.with inadeq.resons.poss.addit.benefit   Ca, screen ulcerat.colit.pts.at incr. risk/ hist of dysplas./colon Ca.for   with meds.interfer.with enterohepat.re-circulat., bioavail.reduc.with
   with incr.dos.freq.to 40 mg wkly. Reconsid.incr.dos. freq.in pts.with   dysplas.at reg. interv. bef./dur.ther., latex hypersens., discont. ther. if   concom. tobramycin/cefuroxime in liv.transpl.pts. apppar.by inhibit.
   inadeq.respons.aft.24 wks.   signific.haemtolog.abnormalit.confirm., concom. anakinra/abatacept   of enterohepat.recirculat., expos. reduc. by norfloxac/metronidaz/
   Hidradenit.suppurativa: Adults: 160 mg on Day 1 (admin.as   not recomm., ensure paed. pts.uptodate with immunisat.guidelines   ciprofloxac.& amoxicill. & clavulan.acid combinat.
   four 40 mg inj.in one day or as two 40 mg inj./day x2 consec.days),   prior to init.treatm., concurr.liv.vacc.not recomm.& x5 mnths. to infts.
   then 80 mg 2 wks.lat. on day 15 (given as two 40 mg inj.in one day)   born to mothers who became pregn. dur.ther., HF of NYHA class I/  MYCOCEPT 500, Sandoz [P/S]
   follow. 2 wks.later (day 29)by 40 mg every wk. Contin. antibiot.if   II, discont.in pres. of new/worsen CHF sympts., discont.if sympts.   Mycophenolate mofetil
   necess. Treatm.may be re-introduc. if treat.interrupt. Recons.ther.  suggest.of lupus-like syndr.develop, high. incid. of infects.in elderly,   Indications: Organ reject.prophylax.in allogeneic ren./hepat.or card.
   if no benef. aft.12 wks.     do not use in pregn/ breastfeed., delay breastfeed.x5 mnths aft.last   transplants concom.with cyclosporin & corticoster.
   Uveitis: Adults: Init.80 mg follow.by 40 mg every other wk.start.1   inj., use not stud.in childr.&lt;2 yrs.& &lt;6yrs.with Crohn’s dis., new onset.  (S4) TABS, 43/32.2/0241
   wk.aft.init.dos.             psorias.& worsen.of pre-exist. psorias. report.with TNF block.often   718504-001: 500 mg, 50, R1 106,96</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page362.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page358.html">358</a>&nbsp;&nbsp;&nbsp;<a href="page359.html">359</a>&nbsp;&nbsp;&nbsp;<a href="page360.html">360</a>&nbsp;&nbsp;&nbsp;<a href="page361.html">361</a>&nbsp;&nbsp;&nbsp;<a href="page362.html">362</a>&nbsp;&nbsp;&nbsp;<a href="page363.html">363</a>&nbsp;&nbsp;&nbsp;<a href="page364.html">364</a>&nbsp;&nbsp;&nbsp;<a href="page365.html">365</a>&nbsp;&nbsp;&nbsp;<a href="page366.html">366</a>&nbsp;&nbsp;&nbsp;<a href="page367.html">367</a>&nbsp;&nbsp;&nbsp;<a href="page368.html">368</a>
             </td>
             <td width="35%"><a href="page364.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page364.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
